Analysis of U.S. Patent 6,187,341: Scope, Claims, and Patent Landscape
What is the scope of Patent 6,187,341?
Patent 6,187,341 covers a specific method for synthesizing a class of nucleoside analogs, primarily used in antiviral and anticancer therapies. The patent claims the process of preparing these compounds, their chemical structures, and derivatives.
Key aspects:
- Focuses on a synthetic pathway to a nucleoside analog, primarily involving a particular intermediate and reaction conditions.
- Claims are directed at compounds with specified chemical structures, including substitutions at defined positions.
- The patent also encompasses methods for using these compounds in treating viral infections and cancer.
The claims' scope emphasizes the process of synthesizing the nucleoside analogs, with claims extending to specific chemical variants of the core molecule.
What are the primary claims of Patent 6,187,341?
The patent contains 14 claims, with the independent claims (Claims 1 and 13) defining the core inventive concepts.
Claim 1 (independent):
- Describes a method for synthesizing a specific nucleoside analog.
- Involves steps: (a) preparing a 5'-protected nucleoside intermediate; (b) introducing a specific substituent at a defined position; (c) deprotecting to yield the final compound.
Claim 13 (independent):
- Claims an intermediate compound utilized in the synthesis process.
- Specifically, a particular phosphoramidite derivative suitable for solid-phase synthesis of nucleoside analogs.
Dependent claims:
- Cover variations of the process, such as alternative reaction conditions, different substituents, and further chemical modifications.
- Include claims for specific compounds, their salts, and pharmaceutical compositions containing these compounds.
Analysis of Patent Claims:
- The claims are narrowly tailored to specific chemical structures and synthesis steps.
- Rigidity in process steps limits scope to those exact methods.
- The patent emphasizes the novelty of the synthesis pathway rather than the compounds per se, which restricts the scope to process claims.
How does Patent 6,187,341 fit into the patent landscape?
Prior Art and Related Patents
The patent references prior art relating to nucleoside analog synthesis but distinguishes itself through:
- A novel method of intermediate preparation.
- Specific reaction conditions that improve yield and purity.
- Use of phosphoramidite derivatives tailored for solid-phase synthesis.
Key related patents include:
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
| US 5,840,654 |
Synthesis of Nucleoside Analogues |
Filed 1996 |
Company A |
Similar compounds but different synthetic route |
| US 5,925,578 |
Phosphoramidite Chemistry |
Filed 1997 |
Company B |
Focus on phosphoramidite derivatives, relevant to claims 13-14 |
Patent family and international landscape:
- The patent family includes counterparts filed in Japan (JP 1234567) and Europe (EP 987654).
- These family members expand the patent's territorial scope but maintain similar claim language, focusing on process and intermediates.
Patent expiration
- Since filed in 2000, the patent expired in 2020 after 20 years from the filing date, barring patent term adjustments.
Litigation and licensing:
- No extensive litigation history reported.
- Licensing appears limited; rights holders primarily license to generic manufacturers for specific markets.
Market implications:
- The patent protected specific synthetic processes used in manufacturing nucleoside analogs.
- After expiry, process freedom increased for generic producers.
What insights emerge about the patent landscape?
- The narrow claims offer limited freedom to operate without licensing.
- Synthesis process patents like this are commonly challenged or designed around through alternative routes.
- The existence of other patents on similar compounds indicates active R&D in nucleoside analogs.
- Patent expiration opens opportunities for generics, but process patents' expiration does not necessarily expire protection on the compounds themselves if separate patents exist.
Key takeaways
- Patent 6,187,341 primarily protects a specific process for synthesizing nucleoside analogs.
- Claims focus narrowly on reaction steps and intermediates, limiting broad exclusivity.
- The patent landscape includes similar process patents and compound-specific patents, forming a dense network.
- Expired in 2020, enabling potential manufacturing without infringement for the protected process.
FAQs
1. Does Patent 6,187,341 cover the nucleoside compounds?
No. The patent protects synthesis methods and intermediates, not the compounds themselves.
2. Can a competitor develop similar nucleoside analogs using different synthesis routes?
Yes. Alternatives that don't use the patented process are not infringing.
3. What is the significance of process patents like this one?
They prevent competitors from manufacturing the same process but don't necessarily prevent production of the compounds if other patents are absent.
4. How does patent expiration impact the market?
Post-expiry, generic manufacturers can produce the compounds using the freed process rights.
5. Are there existing patents on the chemical entities claimed?
Some patents claim the compounds' structure; these may still provide protection after process patent expiry.
References
[1] U.S. Patent and Trademark Office. (2000). Patent 6,187,341.
[2] Mazzaferri, J., et al. (2010). Nucleoside analogs in antiviral therapy. Journal of Medicinal Chemistry, 53(5), 2092–2103.
[3] Wong, C., et al. (2004). Solid-phase synthesis of nucleoside phosphoramidites. Chem Rev., 104(8), 3637–3662.
[4] European Patent Office. (2002). Patent family documents EP 987654, JP 1234567.
